Patient 2, diagnosed with acute lymphoblastic B-cell leukaemia, received anti-CD19 and anti-CD22 CAR-T-cell cocktail therapy and remained in complete remission for over 4 years. This evidence concerns the gene CD22 and precursor B-cell acute lymphoblastic leukemia.